{"disease":{"id":"neuroendocrine-tumor","name":"Neuroendocrine tumor","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":23},"drugs":{"marketed":[{"drug_id":"everolimus","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"lutetium-177lu-oxodotreotide","indication_name":"Neuroendocrine tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lutathera","generic_name":"lutetium (177Lu) oxodotreotide","company_name":"Aaa Usa Inc","drug_phase":"marketed","molecular_target":"Somatostatin receptor type 2","drug_class":"","quality_score":59,"revenue":"190","mechanism":"Lutathera works by binding to somatostatin receptors on neuroendocrine tumor cells, delivering a radioactive dose that kills the cells."},{"drug_id":"edotreotide","indication_name":"somatostatin receptor positive neuroendocrine tumors (NETs)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ga-68-DOTATOC","generic_name":"EDOTREOTIDE","company_name":"Uihc Pet Imaging","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":43,"revenue":null,"mechanism":"Ga-68-DOTATOC works by binding to somatostatin receptors on the surface of certain tumor cells, allowing them to be visualized through PET imaging."},{"drug_id":"sunitinib","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"sunitinib-malate","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sunitinib Malate","generic_name":"sunitinib-malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":80,"revenue":null,"mechanism":"Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET."},{"drug_id":"afinitor","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"sutent","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"Sunitinib Malate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET","drug_class":"Small molecule kinase inhibitor","quality_score":67,"revenue":null,"mechanism":"Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression."},{"drug_id":"pentetreotide","indication_name":"primary neuroendocrine tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Octreoscan","generic_name":"PENTETREOTIDE","company_name":"Sun Pharm Inds Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"pentetreotide","indication_name":"metastatic neuroendocrine tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Octreoscan","generic_name":"PENTETREOTIDE","company_name":"Sun Pharm Inds Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"sunitinib","indication_name":"Pancreatic Neuroendocrine Tumors (pNET)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sutent","generic_name":"sunitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-phosphoinositide-dependent protein kinase 1","drug_class":"Moderate Risk QT Prolonging Agents","quality_score":67,"revenue":null,"mechanism":"Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT."},{"drug_id":"streptozotocin","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Streptozotocin","company_name":"Hoffmann-La Roche","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"streptozocin","indication_name":"Pancreatic Neuroendocrine Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zanosar","generic_name":"STREPTOZOCIN","company_name":"Teva","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":12,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06344507","title":"Iconographic Registry of Pancreatobiliary Endoscopy Procedures","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT04949282","title":"Spanish Series of Patients Treated With the Radionuclide Lutetium177","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Sociedad Española de Medicina Nuclear e Imagen Molecular","has_results":false},{"nct_id":"NCT04847505","title":"68Ga-DOTA-TATE PET/CT Imaging in NETs","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","has_results":false},{"nct_id":"NCT04282083","title":"Protocol ITANET - Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Italian Association Neuroendocrine Tumors","has_results":false},{"nct_id":"NCT06787014","title":"Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study","phase":"","overall_status":"RECRUITING","enrollment_count":3200,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT05693519","title":"GastroIntestinal Cancer in Children and Adolescents","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Paul G. Kemps, MD","has_results":false},{"nct_id":"NCT02810600","title":"Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors","phase":"","overall_status":"COMPLETED","enrollment_count":2120,"lead_sponsor_name":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","has_results":false},{"nct_id":"NCT06041009","title":"Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations","phase":"","overall_status":"RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT02146170","title":"Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07439757","title":"AI-Powered Precision Decision-Making for Pancreatic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT03873870","title":"68Ga-DOTATATE PET for Management of Neuroendocrine Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":1916,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT00923026","title":"Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03691064","title":"Post-Authorization Long-Term Safety Study of LUTATHERA","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1014,"lead_sponsor_name":"Advanced Accelerator Applications","has_results":false},{"nct_id":"NCT05847855","title":"Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06607198","title":"Clinical-pathological Evaluation of Pit-NETs","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":940,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06679816","title":"Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":882,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06159920","title":"Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors.","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT05427032","title":"HRQoL During PRRT in Patients With NETs","phase":"","overall_status":"COMPLETED","enrollment_count":756,"lead_sponsor_name":"Uppsala University","has_results":false},{"nct_id":"NCT06523582","title":"Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Universidad Nacional Autonoma de Mexico","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04074135","title":"Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":740,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06983106","title":"Correlation Between Body Composition and Pathologic Grade/Prognosis in GEP-NENs: A Retrospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":633,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT02102893","title":"Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"National Health Research Institutes, Taiwan","has_results":false},{"nct_id":"NCT04888481","title":"68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT07389512","title":"Pharmaceutical Management in Targeted Radioligand Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06143605","title":"Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":527,"lead_sponsor_name":"Yanhong Deng","has_results":false},{"nct_id":"NCT05804331","title":"The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Western Sydney Local Health District","has_results":false},{"nct_id":"NCT06300216","title":"A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT05673031","title":"68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Alberta Health services","has_results":false},{"nct_id":"NCT06356467","title":"Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05565066","title":"A Real-world Comparison of FNB and FNA in IHC-required Lesions.","phase":"","overall_status":"COMPLETED","enrollment_count":439,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT00569127","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":427,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02630654","title":"Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs","phase":"","overall_status":"COMPLETED","enrollment_count":404,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04788927","title":"Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05334290","title":"Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Massimo Falconi","has_results":false},{"nct_id":"NCT03042416","title":"18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT04986085","title":"Nutrition in Gastroenteropancreatic Neuroendocrine Tumor","phase":"","overall_status":"COMPLETED","enrollment_count":399,"lead_sponsor_name":"Grupo Espanol de Tumores Neuroendocrinos","has_results":true},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT07272512","title":"Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT05647954","title":"A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"Taizhou Hanzhong biomedical co. LTD","has_results":false},{"nct_id":"NCT05844332","title":"LUTATHERA Injection General Use Result Survey","phase":"","overall_status":"COMPLETED","enrollment_count":347,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03288402","title":"Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":346,"lead_sponsor_name":"University Hospitals Coventry and Warwickshire NHS Trust","has_results":false},{"nct_id":"NCT01967537","title":"Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":341,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}